Director Declaration

RNS Number : 6272K

Indivior PLC

11 April 2018

 

Indivior PLC (the 'Company')

Indivior PLC confirms that Mr Daniel Tassé, Senior Independent Director, was appointed as an independent director of HLS Therapeutics Inc., a specialty pharmaceutical company listed on the TSX Venture Exchange, with effect from March 14, 2018.

This announcement is made in accordance with Listing Rule 9.6.14.

Kathryn Hudson

Company Secretary

 

END

 

 

RDNFKDDKPBKDDQD